Management of Post-transplant hyperlipidemia
|
|
- Gervais Conley
- 6 years ago
- Views:
Transcription
1 Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and Metabolism Vanderbilt University Medical Center
2 Learning objectives Interpret / understand a lipid profile Identify mechanisms associated to post transplant dyslipidemia Become familiar with treatment options for different cholesterol disorders in transplant patients
3 UNDERSTANDING A LIPID PROFILE
4 Components: Lipid profile Total Cholesterol Triglycerides HDL-C (high density lipoprotein) LDL-C* (low density lipoprotein) * Calculated value. If Tg > 400 mg/dl LDL cannot be calculated and needs to be measured.
5 Normal Values (adults) Total cholesterol Triglycerides HDL LDL < 200 mg/dl < 150 mg/dl >40 mg/dl (men) >50 mg/dl (women) < 130 mg/dl Adapted from Journal of Clinical Lipidology, 2014 (8):
6 Most common dyslipidemias Hypercholesterolemia Mixed hyperlipidemia Hypertriglyceridemia
7 Lipid Clinic 3 new patients Mrs. A Mr. B Ms. C
8 Mrs. A Normal range Patient s results TC < Tg < HDL >50 49 LDL < Hypercholesterolemia Cholesterol values are in mg/dl.
9 Normal range Mr. B Patient s results TC < Tg < HDL >40 36 LDL < Hypertriglyceridemia Cholesterol values are in mg/dl.
10 Ms. C Normal range Patient s results TC < Tg < HDL >50 74 LDL < Mixed Hyperlipidemia Cholesterol values are in mg/dl.
11 TRANSPLANT & HYPERLIPIDEMIA
12 Transplant & Hyperlipidemia Prevalence Immunosuppressive drugs Cardiovascular disease & Tx Risk factors
13 Transplant & Hyperlipidemia Prevalence Immunosuppressive drugs Cardiovascular disease & Tx Risk factors
14 Percentage Prevalence of hyperlipidemia in transplant recipients Heart Lung Liver Kidney HCT HCT= allogenic hematopoietic stem cell transplantation World J Transplant 2016;6(1): Ther Adv Endcorinol Metab 2016;7(3) Current pharmaceutical design, 2006 (12): Cardiol Clin 21(2003) Bio Blood Marrow Transplant 2015(21):
15 Percentage Prevalence of hypercholesterolemia in transplant recipients Lung Liver Kidney World J Transplant 2016;6(1): Ther Adv Endcorinol Metab 2016;7(3) Current pharmaceutical design, 2006 (12): Cardiol Clin 21(2003) Bio Blood Marrow Transplant 2015(21):
16 Percentage Prevalence of hypertriglyceridemia on transplant recipients Lung Liver Kidney HCT HCT= allogenic hematopoietic stem cell transplantation World J Transplant 2016;6(1): Ther Adv Endcorinol Metab 2016;7(3) Current pharmaceutical design, 2006 (12): Cardiol Clin 21(2003) Bio Blood Marrow Transplant 2015(21):
17 Prevalence of dyslipidemia in kidney transplant recipients Lipid component % of patients Mean ± SD Total Cholesterol > ± 81 LDL > ± 53 HDL < ± 15 Triglycerides 195 ± 106 Am J Transplant. 2004;4 Suppl 7:13
18 Transplant & Hyperlipidemia Prevalence Immunosuppressive drugs Cardiovascular disease & Tx Risk factors
19 J Heart Lung Transplant 2005:24: Current pharmaceutical design, 2006 (12): World J Transplant 2016;6(1): Cardiovascular disease (CVD) & transplant CVD is a common cause of morbidity and mortality among long term transplant survivors 1 st cause of death: heart & kidney transplant recipients 2 nd cause of death: liver transplant recipients Atherosclerosis accelerated after transplantation
20 Hyperlipidemia & transplant Incidence after organ transplantation Risk factor for CVD: Interventions to treat hyperlipidemia: cardiac deaths and non-fatal MI in clinical trials specific to the transplant population Important for improving outcome after transplant. Lowers cardiovascular risk Risk factor for long-term graft loss: hyperlipidemia is a possible contributor to chronic kidney allograft injury as a non immune risk factor World J Transplant 2016;6(1):
21 ALERT Trial Assessment of Lescol in Renal Transplantation RCT, double blind, placebo controlled 2102 renal transplant recipients taking cyclosporine (TC mg/dl), age Fluvastatin mg (n=1050) or Placebo (n=1052) for 5-6 yrs 1ary endpoint: Major Adverse Cardiac Event (cardiac death, nonfatal MI or coronary intervention procedure) Lancet 2003;361:
22 ALERT Trial - Results Mean follow up: 5.1 yrs Adverse effects: similar in both groups Fluvastatin lowered LDL-C by 32% Risk reduction for 1ary end-point: not significant RR 0.83 (95% CI, , p=0.139) Lancet 2003;361:
23 ALERT Trial Post hoc analysis Fluvastatin therapy was associated: 38% risk of cardiac death (p=0.031) 32% risk for definite nonfatal MI (p=0.048) Significant risk reduction of the combined end point (cardiac death & non fatal MI) by 35% (p=0.005)
24 ASCVD atherosclerotic cardiovascular disease KDIGO 2013, Vol 3, issue 3 Renal transplant & CV disease risk National Kidney Foundation Kidney Disease Quality Outcomes Initiative guidelines: Transplanted patients are included in the highest risk category (considered in the highest ASCVD risk group) (2004) Consider renal transplant as a coronary heart disease equivalent risk (2004) Statins should be prescribed adults >30 yrs. of age & s/p kidney transplant regardless of their baseline cholesterol level (2013) Absence of guidelines for other transplant recipients consider placing these patients in the high risk category
25 Hyperlipidemia & heart transplant Treatment is indicated: Prevent progression of atherosclerosis in native vessels outside the heart Slows the development of transplant vasculopathy
26 Statins & heart transplant RCTs have shown that pravastatin & simvastatin Improve survival incidence of acute rejection transplant vasculopathy All patients receive a statin after cardiac transplantation regardless of their baseline LDL-C
27 Transplant & Hyperlipidemia Prevalence Immunosuppressive drugs Cardiovascular disease & Tx Risk factors
28 Non modifiable risk factors Gender Family history Advancing age Pre transplant hyperlipidemia Development of diabetes Hypothyroidism Proteinuria / kidney dysfunction
29 Medications Modifiable risk factors Immunosuppression Lifestyle Weight gain / Diet Excessive alcohol intake Lack of exercise
30 Transplant & Hyperlipidemia Prevalence Immunosuppressive drugs Cardiovascular disease & Tx Risk factors
31 Immunosuppression & hyperlipidemia Calcineurin inhibitors Cyclosporine - LDL Tacrolimus LDL (possibly) Antimetabolites Azathioprine Mycophenolate sodium
32 Immunosuppression & hyperlipidemia mtor Inhibitor Sirolimus LDL & Tg Everolimus LDL Corticosteroids Tg & LDL
33 Calcineurin inhibitors Cyclosporine & Tacrolimus - Cyclosporine: - Binds to the LDL-R LDL-C levels - activity of hepatic lipase LDL - activity of lipoprotein lipase - bile acid synthesis down regulates LDL-R - Highly lipophilic, it is transported in LDL-C particles - Effect is dose dependent - Tacrolimus: - Produces less lipid disturbance TC, Tg, VLDL & LDL Ther Adv Endcorinol Metab 2016;7(3)
34 Conversion from cyclosporine to tacrolimus 124 patients, 1 yr. s/p kidney transplant Randomized: a) cyclosporine b) conversion to tacrolimus At 6 months: Cyclosporine Tacrolimus LDL (mg/dl) Tg (mg/dl) J Am Soc Nephrol. 2003;14(7):1880
35 mtor Inhibitor Sirolimus Sirolimus: Impairs lipoprotein lipase secretion of VLDL May cause hepatic over production of lipoprotein Dose dependent effect TC, Tg & LDL
36 Corticosteroids - Increase: - FFA synthetase - hepatic synthesis of VLDL - VLDL LDL - HMG-CoA reductase activity - Decrease: - lipoprotein lipase activity - synthesis of LDL-R Tg, TC, LDL & HDL Ther Adv Endcorinol Metab 2016;7(3) Current pharmaceutical design, 2006 (12):
37 Balancing immunosuppression & hyperlipidemia Immunosuppressive therapy takes precedence over dyslipidemic therapy Dyslipidemia may be tolerated, even if it cannot be treated optimally Possible changes in immunosuppression: Cyclosporine tacrolimus Stop sirolimus Low dose steroids
38 Evaluation of dyslipidemia in transplant Pre / post transplant recipients Fasting lipid panel 3 months follow up Annually
39 When should a lipid panel be checked? 2013 KDIGO guidelines Initial presentation Suggest No follow up is required for many patients Follow up when results will alter management Reasons to repeat a lipid panel Assessment of adherence Concern about the presence of a new secondary cause for dyslipidemia KDIGO 2013, Vol 3, issue 3
40 When should a lipid panel be checked? cont. American Association for the Study of Liver Disease 2012 Guidelines Measurement of a fasting lipid panel annually s/p hematopoietic stem cell transplant patients Annual fasting lipid panel Patients on immunosuppression Have chronic GVHD Previous abnormal lipid profile Blood 2011;117(11):
41 TREATMENT OF POST TRANSPLANT HYPERLIPIDEMIA
42 Treatment overview Non-pharmacologic Pharmacologic
43 Therapeutic lifestyle changes Diet: Saturated fat <7% of total calories Total fat 25-35% of total calories Carbohydrates 50-60% of total calories Fiber g per day American Journal of Transplantation 2004 (4) 13-53
44 Therapeutic lifestyle changes cont. Physical Activity: 3-4 times per week minutes Habits: Smoking cessation Alcohol in moderation American Journal of Transplantation 2004 (4) 13-53
45 Treatment of hypercholesterolemia LDL % Statins Cholesterol absorption inhibitor 18 Bile acid sequestrants Nicotinic acid 5-25 Lipid academy 9/2015,
46 Management of hypercholesterolemia in transplant recipients Goal: LDL < 100 mg/dl* Initiate LDL-C > 100 mg/dl Therapeutic lifestyle change 3 months + low dose statin Alternative Ezetimibe * If the patient has a history of ASCVD goal <70 mg/dl American Journal of Transplantation 2012(12): Practice guideline by AASLD and the American Society of Transplantation
47 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin
48 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Block cholesterol synthesis Upregulate LDL receptors Modulate inflammatory molecules Clinically proven to mortality & recurrent cardiovascular events
49 Percentage change in LDL cholesterol STELLAR Trial Rosuvastatin Atorvastatin Simvastatin Pravastatin mg 20 mg 40 mg 80 mg Am J Cardiol 2003; 92:
50 Statin doses Atorvastatin Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin 40 mg 20 mg 1 mg 20 mg 10 mg 10 mg 80 mg 40 mg 2 mg 40 mg 20 mg 20 mg 80 mg 4 mg 80 mg 5 mg 40 mg 40 mg 10 mg 80 mg 80 mg 20 mg 40 mg
51 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Side effects: 5-10% myopathy (rhabdomyolysis) Development of diabetes mellitus Memory problems
52 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Risk of myopathy is greatest Elderly GFR < 30 ml/min Maximum statin dose Combination with CYP450 inhibitors
53 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Patient reports myalgias check a CK 3 to 5 times upper limit of normal recheck the level weekly > 5 times upper limit of normal d/c Am Heart J 2004;148: v
54 Incidence of fatal rhabdomyolysis Per 1 million prescriptions by drugs is: Fluvastatin 0% Pravastatin 0.04% Atorvastatin 0.04% Simvastatin 0.12% Am Heart J 2004;148:
55 Statin drug-drug interaction Simvastatin and lovastatin Metabolized CYP450-3A4 Contraindicated with cyclosporine Rosuvastatin Maximum dose is 5 mg /daily when used with cyclosporine Fibrates Gemfibrozil inhibits glucuronidation and uptake of active forms by OATP1B1 transporter by the liver
56 KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease, 2004
57 Recommended statin doses for adults s/p kidney transplant Statin mg/d Fluvastatin (40)-80 Atorvastatin (10)-20 Rosuvastatin (5)- 10 Simvastatin / ezetimibe 20/10 Pravastatin (20)-40 Simvastatin (20)- 40 Pitavastatin 2 Doses in ( ) are starting doses and recommended doses when patients are in cyclosporine Lipid abnormalities after renal transplantation uptodate.com KDIGO 2013, Vol 3, issue 3
58 KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease, 2004
59 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Binds to cholesterol transporter & blocks its absorption May increase LDL-R Courtesy of MacRae Linton, MD
60 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Ezetimibe 10 mg daily 2 nd choice in patients who do not tolerate a statin Used in combination with a statin Smaller dose (5mg/daily?) due to its interaction with cyclosporine which can induce a 2 to 12 fold in ezetimibe levels
61 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Low risk of serious side effects Reports: Myalgias Rhabdomyolysis Hepatitis Acute pancreatitis Thrombocytopenia
62 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin hepatic bile acid pool hepatic bile acid synthesis from cholesterol intrahepatic cholesterol pool LDL-C LDL clearance LDL receptors
63 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Gastrointestinal side effects most common Interfere with the absorption of the immunosuppressive drugs Can raise triglycerides Should be separately administered from them: 1 hour before 4 hours after
64 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin release of fatty acids from adipose tissue FFA Tg synthesis VLDL secretion LDL-C
65 Statins Cholesterol absorption inhibitor Bile acid sequestrants Niacin Side effects: Flushing Hepatotoxicity Hyperglycemia Hyperuricemia Gastrointestinal discomfort (nausea, vomiting, dyspepsia)
66 Hypertriglyceridemia Indication for pharmacologic treatment: Tg > 500 (1000) mg/dl Goal prevent pancreatitis (Tg > 1000 mg/dl)
67 Hypertriglyceridemia cont. Treat secondary etiology Diseases: Diabetes Nephrotic syndrome Lifestyle: Diet high in simple carbohydrates Alcohol
68 Hypertriglyceridemia cont. Drugs: Immunosuppressant agents Estrogen Glucocorticoids Beta blockers Retinoids
69 Hypertriglyceridemia management Tg < 500 mg/dl Lifestyle modification Tg > 500 mg/dl Fibrates Fenofibrate Gemfibrozil Omega 3 fatty acids (DHA & EPA) 4 grams daily (2 grs bid)
70 Treatment of hypertriglyceridemia Tg % reduction Fibrates Omega-3 fatty acids 45 Statins 7-30 Nicotinic acid Lipid academy 9/2015,
71 Fibrates Activate PPAR α Omega 3 fatty acids hepatic VLDL cholesterol synthesis lipoprotein lipase activity Doses adjusted according to the patient s kidney function KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease, 2004 The American Journal of Cardiology, 2007 (99): 3C-18C
72 Fibrates Omega 3 fatty acids Adverse effects: GI dyspepsia, diarrhea Increase LFTs May potentiate action of anticoagulation Contraindications Hepatic impairment Pre-existing gallbladder disease
73 Fibrates Omega 3 fatty acids May reversibly creatinine Myotoxicity fenofibrate is preferred over gemfibrozil when added to a statin
74 Fibrates In transplant Omega 3 fatty acids Evidence supporting the safety and efficacy of fibrate use is weak Dose adjusted for kidney function Not recommended Only on Tg >1000 mg/dl KDIGO 2013, Vol 3, issue 3
75 Fibrates Omega 3 fatty acids Unclear mechanism of action EPA eicosapentaenoic acid DHA docosahexaenoic acid Omega-3: four grams daily (divided doses)
76
77 When should you refer a patient to a lipid specialist? If the patient s LDL > 190 mg/d or triglycerides >1000 mg/dl The patient has a prior history of intolerance to cholesterol lowering medications If combination therapy is not controlling your patient s cholesterol level
78 THANKS Lipid Clinic - Vanderbilt Heart and Vascular Institute (615)
Antihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationMajor recommendations for statin therapy for ASCVD prevention
2013 A/AHA Guidelines holesterol Rx to Reduce ASVD Risk in Adults Major recommendations for statin therapy for ASVD prevention *% in LDL can be used as indication of response & adherence to Rx but is not
More information2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2
2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2 GOALS ACC/AHA as publisher of guidelines Determining which patients are appropriate for statin therapy The treatment
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationPodcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam
Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationCPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction
CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationFinancial Disclosures
1 Lipids in Type 2 Diabetes July 20, 2013 Abhimanyu Garg, M.D. Professor of Internal Medicine Chief, Division of Nutrition and Metabolic Diseases Distinguished Chair in Human Nutrition Research UT Southwestern
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationDyslipidemia. (Med-341)
Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationCopy right protected Page 1
CHOLESTEROL and TGs LOWERING DRUGS Introduction: Fat (lipids) are combinations (esters) of fatty acids plus an alcohol. The two main fats in the body are triglycerides (TGs) and cholesterol Triglycerides
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationDrugs for Dyslipidemias
Drugs for Dyslipidemias HMG CoA reductase inhibitors (statins): atorvastatin, lovastatin, pravastatin, simvastatin Bile acid-binding resins: cholestyramine, colestipol, colesevelam Fibric acid derivatives
More informationDyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan
Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationIntroduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)
Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationVincent J. Caracciolo, MD FACC FOMA May 2014
Vincent J. Caracciolo, MD FACC FOMA May 2014 Goals of the Guidelines National Heart, lung and Blood Institute ( NHLBI) collaborated with ACC/AHA to develop guidelines a.) assess CV risk, b.) lifestyle
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationClassification. Etiology
Dyslipidemia Dyslipidemia is the elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein level that contributes to the development of atherosclerosis. Causes may
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationCLINICAL IMPORTANCE OF LIPOPROTEINS
25 Hyperlipidemias CLINICAL IMPORTANCE OF LIPOPROTEINS Raised levels of low-density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol are independent risk factor
More information2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationLecture 36 Dyslipidemia Therapeutics Barry LIPIDS:
LIPIDS: PATHOPHYSIOLOGY: TC or LDL-C = CVD HDL-C = CVD Association between TG and CVD not established o HyperTG associated with pancreatitis o Reducing TG w/ drug therapy doesn t CVD TYPES OF DYSLIPIDEMIA:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More information10/4/2016. Similarities between the ACC/AHA Guidelines and the NLA Recommendations
Lipid Management CoxHealth Heart and Vascular Summit Oct 15, 2016 DISCLOSURES I have no potential conflicts of interest and nothing relevant to this lecture to disclose Learning Objectives Develop an evidence-based
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationTreating dyslipidemia
Treating dyslipidemia in patients with type 2 diabetes mellitus 18 The Nurse Practitioner Vol. 40, No. 18 www.tnpj.com 2.0 CONTACT HOURS 1.0 CONTACT HOURS Abstract: Type 2 diabetes mellitus is associated
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More information